Olinciguat

Phase 2Small molecule

CCyclerion Therapeutics

Olinciguat is one of 5 small molecule programs targeting Achalasia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AchalasiaActive, not recruiting

AchalasiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Achalasia

#DrugCompanyPhaseTrials

Avycaz

PPhiladelphia Eye Associates

Myrbetriq

1 3

Botox

RRevance Therapeutics, Inc.

Preclinical

2 4

Olinciguat

CCyclerion Therapeutics

Phase 2

1 5

Second Generation Cephalosporin

SShanghai Zhongshan Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Trial1 trial

A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers

Completed·CCyclerion Therapeutics·Phase 1·NCT03892499·24 enrolled

Achalasia1 trial

Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

Terminated·CCyclerion Therapeutics·Phase 2·NCT02931565·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Olinciguat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Olinciguat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Olinciguat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cyclerion Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCyclerion Therapeutics

Olinciguat

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Trial1 trial

Achalasia1 trial

References

Drug Info

Quick Facts

Related News